Seer, Inc. (SEER) Earnings Call Analysis

NASDAQ · Healthcare · Biotechnology

10/25

Growth 1 Margin 2 Expansion 3 Platform 2 Financial 2

latest quarter score

Earnings Reports

10
SEER (SEER) Q2 2026: Revenue Declines 23% Amid Funding Headwinds, Commercial Execution Gains Traction
August 12, 2026
11
SEER (SEER) Q1 2026: Operating Expenses Drop 20% as Biobank Momentum Builds
May 14, 2026
15
SEER (SEER) Q4 2025: Installed Base Jumps 67% as Proteograph Adoption Outpaces Funding Headwinds
February 27, 2026
17
SEER (SEER) Q3 2025: Instrument Shipments Triple, Academic Uptake Surges Despite Funding Headwinds
November 07, 2025
14
SEER (SEER) Q2 2025: ProteoGraph 1 Launch Doubles Throughput, Unlocks 20,000-Sample Population Studies
August 07, 2025
18
Seer (SEER) Q1 2025: 37% Revenue Growth Driven by Population-Scale Proteomics Momentum
May 13, 2025
Seer (SEER) Q4 2024: 24% Revenue Growth Guidance Highlights Transition to Scalable Proteomics Platform
February 27, 2025

Browse all companies